Vanguard Group
CLVS

Vanguard Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Vanguard Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,206,509
Closed -$12.1M – 4580
2022
Q3 		$12.1M Sell
10,206,509
-1,016,728
-9% -$1.58M ﹤0.01% 2859
2022
Q2 		$20.2M Sell
11,223,237
-1,125,661
-9% -$1.66M ﹤0.01% 2636
2022
Q1 		$24.9M Buy
12,348,898
+2,233,797
+22% +$4.39M ﹤0.01% 2652
2021
Q4 		$27.4M Sell
10,115,101
-2,179,790
-18% -$8.06M ﹤0.01% 2670
2021
Q3 		$54.8M Buy
12,294,891
+2,380,823
+24% +$11.5M ﹤0.01% 2310
2021
Q2 		$57.5M Buy
9,914,068
+2,290,875
+30% +$13.4M ﹤0.01% 2293
2021
Q1 		$53.5M Buy
7,623,193
+1,235,639
+19% +$8.28M ﹤0.01% 2276
2020
Q4 		$30.7M Buy
6,387,554
+205,075
+3% +$1.04M ﹤0.01% 2434
2020
Q3 		$36M Sell
6,182,479
-62,445
-1% -$374K ﹤0.01% 2176
2020
Q2 		$42.2M Buy
6,244,924
+1,787,665
+40% +$13.5M ﹤0.01% 2086
2020
Q1 		$28.3M Buy
4,457,259
+238,915
+6% +$1.92M ﹤0.01% 2124
2019
Q4 		$44M Sell
4,218,344
-295,499
-7% -$2.15M ﹤0.01% 2180
2019
Q3 		$17.7M Sell
4,513,843
-67,950
-1% -$550K ﹤0.01% 2542
2019
Q2 		$68.1M Sell
4,581,793
-47,969
-1% -$867K ﹤0.01% 1949
2019
Q1 		$115M Buy
4,629,762
+68,832
+2% +$1.73M ﹤0.01% 1680
2018
Q4 		$81.9M Buy
4,560,930
+115,866
+3% +$2.37M ﹤0.01% 1789
2018
Q3 		$131M Buy
4,445,064
+104,655
+2% +$4.05M 0.01% 1663
2018
Q2 		$197M Buy
4,340,409
+349,031
+9% +$17M 0.01% 1357
2018
Q1 		$211M Buy
3,991,378
+69,426
+2% +$4.05M 0.01% 1257
2017
Q4 		$267M Buy
3,921,952
+51,147
+1% +$3.58M 0.01% 1104
2017
Q3 		$319M Buy
3,870,805
+251,962
+7% +$20M 0.01% 966
2017
Q2 		$339M Buy
3,618,843
+333,648
+10% +$20.4M 0.02% 899
2017
Q1 		$209M Buy
3,285,195
+662,969
+25% +$40.3M 0.01% 1194
2016
Q4 		$116M Buy
2,622,226
+97,762
+4% +$3.44M 0.01% 1524
2016
Q3 		$91M Buy
2,524,464
+118,996
+5% +$2.55M 0.01% 1619
2016
Q2 		$33M Buy
2,405,468
+171,047
+8% +$2.5M ﹤0.01% 2090
2016
Q1 		$42.9M Buy
2,234,421
+1,153
+0.1% +$24.4K ﹤0.01% 1937
2015
Q4 		$78.2M Buy
2,233,268
+169,332
+8% +$10.9M 0.01% 1631
2015
Q3 		$190M Buy
2,063,936
+264,515
+15% +$22.9M 0.01% 1015
2015
Q2 		$158M Buy
1,799,421
+151,772
+9% +$13M 0.01% 1221
2015
Q1 		$122M Buy
1,647,649
+249,857
+18% +$17.6M 0.01% 1360
2014
Q4 		$78.3M Buy
1,397,792
+47,785
+4% +$2.51M 0.01% 1575
2014
Q3 		$61.2M Buy
1,350,007
+6,866
+0.5% +$287K ﹤0.01% 1689
2014
Q2 		$55.6M Buy
1,343,141
+33,065
+3% +$1.7M ﹤0.01% 1778
2014
Q1 		$90.7M Buy
1,310,076
+53,818
+4% +$3.95M 0.01% 1413
2013
Q4 		$75.7M Buy
1,256,258
+223,216
+22% +$12.1M 0.01% 1503
2013
Q3 		$62.8M Buy
1,033,042
+289,154
+39% +$20.5M 0.01% 1566
2013
Q2 		$49.8M Buy
+743,888
New +$33.5M 0.01% 1642

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Vanguard Group's CLVS Position: Q4 2022 in Review

Vanguard Group sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 10,206,509 shares — an estimated $12.1M sold.

Vanguard Group first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $339M in Q2 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Vanguard Group reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Vanguard Group sold 10,206,509 Clovis Oncology, Inc. shares in Q4 2022, an estimated $12.1M.
  • Vanguard Group first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
  • Vanguard Group's Clovis Oncology, Inc. position peaked at $339M in Q2 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.